Should microalbuminuria ever be considered as a renal endpoint in any clinical trial?

American Journal of Nephrology

Volumn 31, Issue 5, 2010, Pages 469-470

  Weir, Matthew R ^a   Bakris, George L ^b  

^a UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALBUMIN; ANGIOTENSIN RECEPTOR ANTAGONIST; ANTIHYPERTENSIVE AGENT; C REACTIVE PROTEIN; BIOLOGICAL MARKER;

BLOOD PRESSURE REGULATION; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL STUDY; DIABETIC NEPHROPATHY; EDITORIAL; GLOMERULUS FILTRATION RATE; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FAILURE; METABOLIC SYNDROME X; MICROALBUMINURIA; PATIENT ASSESSMENT; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; TREATMENT OUTCOME; ALBUMINURIA; CLINICAL TRIAL; COHORT ANALYSIS; INFLAMMATION; KIDNEY DISEASE; METHODOLOGY; NOTE; RISK FACTOR; STANDARD; URINE;

ALBUMINURIA; BIOLOGICAL MARKERS; CLINICAL TRIALS AS TOPIC; COHORT STUDIES; DIABETIC NEPHROPATHIES; HUMANS; INFLAMMATION; KIDNEY DISEASES; RESEARCH DESIGN; RISK FACTORS; TREATMENT OUTCOME;

EID: 77951075167     PISSN: 02508095     EISSN: None     Source Type: Journal    
DOI: 10.1159/000292500     Document Type: Editorial

References (9)

1. Mauer M, Zinman B, Gardiner R, et al: Renal and retinal effects of enalapril and losartan in type 1 diabetes. N Engl J Med 2009; 361: 40-51.
2. Steinke JM, Sinaiko AR, Kramer MS, Suissa S, Chavers BM, Mauer M: The early natural history of nephropathy in type 1 diabetes: III. Predictors of 5-year urinary albumin excretion rate patterns in initially normoalbuminuric patients. Diabetes 2005; 54: 2164-2171.
3. Perkins BA, Ficociello LH, Roshan B, Warram JH, Krolewski AS: In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria. Kidney Int 2010; 77: 57-64.
4. Kalaitzidis R, Bakris G: Pathogenesis and treatment of microalbuminuria in patients with diabetes: the road ahead. J Clin Hypertens (Greenwich) 2009; 11: 636-643.
5. Rocco A, Heerlein K, Diedler J, et al: Microalbuminuria in cerebrovascular disease: a modifiable risk factor? Int J Stroke 2010; 5: 30-34.
6. So WY, Kong AP, Ma RC, et al: Glomerular filtration rate, cardiorenal end points, and all-cause mortality in type 2 diabetic patients. Diabetes Care 2006; 29: 2046-2052.
7. Weir MR: Microalbuminuria and cardiovascular disease. Clin J Am Soc Nephrol 2007; 2: 581-590.
8. Khwaja A, Throssell D: A critique of the UK NICE guidance for the detection and management of individuals with chronic kidney disease. Nephron Clin Pract 2009; 113:c207-c213.
9. Levey AS, Cattran D, Friedman A, et al: Proteinuria as a surrogate outcome in CKD: report of a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis 2009; 54: 205-226.